Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Mathilde Saint-Ghislain"'
Publikováno v:
International Journal of Women's Dermatology, Vol 7, Iss 5, Pp 552-559 (2021)
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle
Externí odkaz:
https://doaj.org/article/4d599338f3344023b80490533160b3d1
Autor:
Hélène Salaün, Leanne de Koning, Mathilde Saint-Ghislain, Vincent Servois, Toulsie Ramtohul, Agathe Garcia, Alexandre Matet, Nathalie Cassoux, Pascale Mariani, Sophie Piperno-Neumann, Manuel Rodrigues
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience with nivolumab/ipilimumab in m
Externí odkaz:
https://doaj.org/article/5c6e7f0d0a0c4c08a409631e649387d8
Publikováno v:
Histopathology. 82:162-169
The diagnosis, histomolecular classes of breast cancers (luminal A, luminal B, HER2-enriched, and basal-like), and accurate prediction of prognosis are commonly determined using morphological and phenotypical analyses in clinical practice worldwide.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c20590a513d9bd2a304a119f837a59
https://doi.org/10.1111/his.14794
https://doi.org/10.1111/his.14794
Autor:
Stéphane Champiat, Hélène Salaün, Francesca Lucibello, Jean-Yves Scoazec, Benjamin Besse, Ana Ines Lalanne, Etienne Rouleau, Nolwenn Metzger, Mathilde Saint-Ghislain, Thomas Ryckewaert, Sophie Gardrat, Raymond Barnhill, Nathalie Cassoux, Marc-Henri Stern, Olivier Lantz, Leanne de Koning, Aurélien Marabelle, Manuel Rodrigues
Publikováno v:
JCO Precision Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93326ad9c7e4e2c89b2af2fe7fc2e183
https://doi.org/10.1200/po.22.00363
https://doi.org/10.1200/po.22.00363
Autor:
Delphine Loirat, Juliette Logeart, Pauline Vaflard, Aurélien Noret, Mathilde Saint-Ghislain, Edith Borcoman, Audrey Hurgon, Cyrille Cros, Thomas Genevee, Audrey Bellesoeur, Francesco Ricci, Florence Lerebours, Laurence Escalup, Marie-Paule Sablin, François-Clément Bidard, Paul H. Cottu, Jean-Yves Pierga
Publikováno v:
Cancer Research. 82:P2-13
BACKGROUND: The use of two anti-HER2 monoclonal antibodies (mAbs) (pertuzumab and trastuzumab) combined with taxanes is the standard of care for first line treatment in HER2-positive metastatic breast cancer (mBC). Infusion related reactions (IRR) du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08a8acc3938e3a296c731a3b00dfb4a7
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-27
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-27
Autor:
Cindy Neuzillet, Véronique Diéras, Marc-Henri Stern, Philippe Beuzeboc, Mathilde Saint-Ghislain, Manuel Rodrigues, Hélène Salaün, Audrey Bellesoeur
Publikováno v:
Bulletin du Cancer. 109:76-82
PARP inhibitors are effective in different types of tumors such as ovarian, breast, prostate and pancreatic cancer. Many studies are in progress and may lead to prescription evolution. PARP inhibitors prescription is almost reserved to patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::baebff2cf39ef842db3546a7eac9a48b
https://doi.org/10.1016/j.bulcan.2021.09.015
https://doi.org/10.1016/j.bulcan.2021.09.015
Autor:
Casilda Llacer Perez, Zoé Neviere, Mihaela Aldea, Elena Castro, Raffaele Ratta, Aude Flechon, Laurent Lam, Mathilde Beaufils, Anne-Claire Hardy, Karim Fizazi, Mathilde Saint-Ghislain, Francesco Ricci, Brigitte Laguerre, Gwenaelle Gravis, Giulia Baciarello, Philippe Barthélémy, Cedric Pobel, Frank Priou, Florence Joly, Antoine Thiery-Vuillemin, Delphine Borchiellini, Carole Helissey, Emeline Orillard, Guilhem Roubaud
Publikováno v:
European Journal of Cancer. 159:87-97
Background Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::331c6ef71fcd018890f68363d8a66772
https://doi.org/10.1016/j.ejca.2021.09.029
https://doi.org/10.1016/j.ejca.2021.09.029
Autor:
Mathilde Saint-Ghislain, Anne-Céline Derrien, Lionnel Geoffrois, Lauris Gastaud, Thierry Lesimple, Sylvie Negrier, Nicolas Penel, Jean-Emmanuel Kurtz, Yannick Le Corre, Caroline Dutriaux, Sophie Gardrat, Raymond Barnhill, Alexandre Matet, Nathalie Cassoux, Alexandre Houy, Toulsie Ramtohul, Vincent Servois, Pascale Mariani, Sophie Piperno-Neumann, Marc-Henri Stern, Manuel Rodrigues
Publikováno v:
European journal of cancer (Oxford, England : 1990). 173
MBD4 mutations have been reported in uveal melanomas, acute myeloid leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a hypermutated phenotype. Although metastatic uveal melanomas (mUM) are usually resistant to immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1008ff585ebc78fcb2d3bee30edcbd
https://pubmed.ncbi.nlm.nih.gov/35863105
https://pubmed.ncbi.nlm.nih.gov/35863105
Publikováno v:
International Journal of Women's Dermatology
International Journal of Women's Dermatology, Vol 7, Iss 5, Pp 552-559 (2021)
International Journal of Women's Dermatology, Vol 7, Iss 5, Pp 552-559 (2021)
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2c35b0df8d7ba16f5d6d71f2582c71f
https://pubmed.ncbi.nlm.nih.gov/35024412
https://pubmed.ncbi.nlm.nih.gov/35024412
Autor:
Hélène, Salaün, Mathilde, Saint-Ghislain, Audrey, Bellesoeur, Philippe, Beuzeboc, Cindy, Neuzillet, Véronique, Diéras, Marc Henri, Stern, Manuel, Rodrigues
Publikováno v:
Bulletin du cancer. 109(1)
PARP inhibitors are effective in different types of tumors such as ovarian, breast, prostate and pancreatic cancer. Many studies are in progress and may lead to prescription evolution. PARP inhibitors prescription is almost reserved to patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::19fae1ed992750722923dcaf2b253278
https://pubmed.ncbi.nlm.nih.gov/34799081
https://pubmed.ncbi.nlm.nih.gov/34799081